Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/14/22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/14/22
Radionetics Oncology Appoints Umesh Gangadharmath, Ph.D. as Senior Vice President, Technical OperationsBusiness Wire • 09/27/22
Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/08/22
New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and MetabolismGlobeNewsWire • 09/02/22
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/12/22
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 08/10/22
Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of NeuroendocrinologyGlobeNewsWire • 08/04/22
Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection PointSeeking Alpha • 06/13/22
Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences ConferenceGlobeNewsWire • 06/07/22
Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose CohortsGlobeNewsWire • 05/25/22
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/12/22
Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes ProgressSeeking Alpha • 04/24/22
Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock OfferingGlobeNewsWire • 04/18/22
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock OfferingGlobeNewsWire • 04/13/22
Radionetics Oncology Appoints Nishan de Silva, M.D. as Chief Executive OfficerBusiness Wire • 04/12/22
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/30/22
Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose CohortsGlobeNewsWire • 03/30/22
Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial OfficerGlobeNewsWire • 03/01/22
Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and Commercialization of Paltusotine in JapanGlobeNewsWire • 02/28/22
Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/09/22